A Phoenix-based digital therapeutics company that has been developing treatments for lazy eye and other ocular disorders has announced its acquisition by New Jersey pharmaceutical giant Novartis.
The acquisition gives a big boost to development of Amblyotech’s digital technology for the treatment of amblyopia, also known as lazy eye.
Early clinical studies published in the Journal of the American Medical Association show the company’s software has demonstrated rapid vision improvements in children and adults compared with a current treatment option of patching.
Amblyotech’s treatment trains patients’ eyes to work together through an approach that combines active gaming and passive video technology with 3D glasses and shows each eye a different image.
